Eli Lilly

Eli Lilly and Company is a global biopharmaceutical firm that discovers, develops, manufactures and markets human therapeutics across multiple therapeutic areas, including endocrinology (notably diabetes and obesity), oncology, immunology and neuroscience. The company primarily focuses on prescription medicines and biologics sold to hospitals, health systems, pharmacies, payers and government purchasers, targeting adult and pediatric patient populations as well as specialist and primary-care providers. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly operates on a global scale with a broad commercial footprint across the Americas, Europe, Asia and other regions, and reports annual revenues above $40 billion in recent years while employing roughly 40,000 people worldwide. Positioned as a major multinational pharmaceutical company, Eli Lilly is publicly listed on the New York Stock Exchange (ticker: LLY) and is recognized for long-standing contributions such as early mass production of insulin and sustained investment in R&D and manufacturing. The company distinguishes itself through a strong pipeline, heavy R&D spending, and recent commercial traction from novel treatments (for example, its dual GIP/GLP-1 candidate) that have driven rapid revenue growth and prompted expanded production capacity. Eli Lilly pursues strategic collaborations with biotechnology firms, academic centers and health systems, funds operations through commercial cash flow and capital markets, and continues to advance regulatory approvals, geographic launches and scale-up of manufacturing to support global demand.